Shares of Eli Lilly and Company (NYSE:LLY) sold by Rockland Trust Co.

Rockland Trust Co. lessened its position in Eli Lilly and Company (NYSE:LLY – Free Report) by 1.5% during the third quarter, HoldingsChannel.com reports. The institutional investor owned 11,418 shares of the company’s stock after selling 173 shares during the quarter. Rockland Trust Co. holdings. in Eli Lilly and Company were worth $10,116,000 as of its most recent SEC filing.

A number of other institutional investors have recently added to or reduced their stakes in LLY. Vanguard Group Inc. raised its stake in shares of Eli Lilly and Company by 1.6% in the first quarter. Vanguard Group Inc. now owns 72,745,011 shares of the company’s stock worth $56,592,709,000 after purchasing an additional 1,133,810 shares during the last quarter. Capital Research Global Investors boosted its holdings in Eli Lilly and Company by 6.0% in the first quarter. Capital Research Global Investors now owns 8,031,531 shares of the company’s stock worth $6,248,210,000 after buying an additional 453,939 shares during the last quarter. Capital International Investors boosted its holdings in Eli Lilly and Company by 5.1% in the first quarter. Capital International Investors now owns 6,972,393 shares of the company’s stock valued at $5,424,243,000 after purchasing an additional 335,560 shares during the last quarter. Fisher Asset Management LLC raised its position in shares of Eli Lilly and Company by 1.9% during the 4th quarter. Fisher Asset Management LLC now owns 4,542,089 shares of the company’s stock, valued at $2,647,675,000 after buying another 85,015 shares in the last quarter. Finally, GQG Partners LLC raised its position in shares of Eli Lilly and Company by 20.2% in the first quarter. GQG Partners LLC now owns 3,848,886 shares of the company’s stock worth $2,994,280,000 after buying an additional 648,094 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company’s shares.

Eli Lilly and Company shares fell 0.7%

Shares of LLY stock opened at $885.15 on Friday. Eli Lilly and Company has a 1 year low of $523.63 and a 1 year high of $972.53. The company has a debt-to-equity ratio of 1.74, a quick ratio of 0.87, and a current ratio of 1.11. The company’s fifty-day moving average is $898.50, and its 200-day moving average is $846.49. The stock has a market cap of $841.25 billion, a PE ratio of 130.36, a price-to-earnings-growth ratio of 2.78 and a beta of 0.42.

Eli Lilly and Company (NYSE:LLY – Get Your Free Report ) last issued its quarterly earnings results on Thursday, August 8th. The company reported $3.92 EPS for the quarter, topping the consensus estimate of $2.64 by $1.28. The firm had revenue of $11.30 billion for the quarter, compared to analysts’ expectations of $9.83 billion. Eli Lilly and Company had a net margin of 18.86% and a return on equity of 67.52%. equities analysts expect that Eli Lilly and Company will post 16.49 earnings per share for the current fiscal year.

Analyst upgrades and downgrades

A number of equities analysts have commented on LLY shares. Wells Fargo & Company raised their price objective on shares of Eli Lilly and Company from $875.00 to $1,000.00 and gave the stock an “overweight” rating in a report on Friday, August 9th. Guggenheim raised their target price on shares of Eli Lilly and Company from $884.00 to $1,030.00 and gave the company a “buy” rating in a report on Friday, August 16th. Jefferies Financial Group boosted their price objective on shares of Eli Lilly and Company from $994.00 to $1,015.00 and gave the company a “buy” rating in a research report on Monday, June 24th. Barclays boosted their price objective on shares of Eli Lilly and Company from $913.00 to $1,025.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 10th. Finally, Morgan Stanley reaffirmed an “overweight” rating and set a $1,106.00 target price on shares of Eli Lilly and Company in a report on Tuesday, August 27th. Three research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. The stock presently has an average rating of “Moderate Buy” and an average price target of $977.35, according to MarketBeat .

Check out the latest stock analysis on LLY

Indoor activity

In other news, major shareholder Lilly Endowment Inc sold 93,593 shares of the company’s stock in a transaction on Monday, July 8th. The shares were sold at an average price of $918.64, for a total transaction of $85,978,273.52. Following the sale, the insider now directly owns 97,153,810 shares of the company’s stock, valued at $89,249,376,018.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC’s website. Insiders own 0.13% of the company’s shares.

Eli Lilly and Company Company Profile

(Free report)

Eli Lilly and Company discovers, develops and markets human pharmaceutical products worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R and Humulin U-500 for diabetes; Jardiance, Mounjaro and Trulicity for type 2 diabetes; and Zepbound for obesity.

Recommended articles

Want to see what other hedge funds own LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY – Free Report).

Get news and reviews for Eli Lilly and Company Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Eli Lilly and Company and related companies with MarketBeat.com’s FREE daily email newsletter.